2338-56-9

Usage

Uses

Used in Industrial Products:
4-Fluoro-2,6-dimethylphenol is used as a preservative in various industrial products such as paints, adhesives, and metalworking fluids. Its preservative qualities help maintain the stability and longevity of these products.
Used in Pharmaceutical Synthesis:
4-FLUORO-2,6-DIMETHYLPHENOL serves as an intermediate in the synthesis of pharmaceuticals and other organic compounds, contributing to the development of new medications and chemical products.
Used in Personal Care Products:
Due to its antimicrobial properties, 4-Fluoro-2,6-dimethylphenol is utilized in some personal care products to ensure cleanliness and prevent microbial growth.
Safety Precautions:
Given its potential toxicity, exposure to 4-fluoro-2,6-dimethylphenol should be limited, and appropriate safety measures should be adhered to during its handling and use.

Upstream product

• 576-26-1 2.6-dimethylphenol 
• 392-70-1 2,6-dimethyl-4-fluoroaniline 
• 3095-38-3 3,5-dimethyl-4-nitrobenzoic acid 
• 315-12-8 2,6-dimethyl-4-fluoro-1-nitro-benzene 
• 34761-82-5 3,5-dimethyl-4-nitroaniline 
• 19023-45-1 3,5-dimethyl-4-nitro-benzoic acid amide 
• 14659-58-6 2‐bromo‐5‐fluoro‐1,3‐dimethylbenzene 
• 289038-20-6 2-bromo-5-fluoro-1,3-dimethylbenzene 

Relevant academic research and scientific papers

Discovery of selective HDAC/BRD4 dual inhibitors as epigenetic probes

According to the binding mode of ABBV-744 with bromodomains and the cape space of HDAC, the novel selective HDAC/BRD4 dual inhibitors were designed and synthesized by the pharmacophore fusion strategy. Evaluating the biomolecular activities through SARs exploration identified three kinds of selective dual inhibitors 41c (HDAC1/BRD4), 43a (pan-HDAC/BRD4) and 43d (HDAC6/BRD4(BD2)), whose target-related cellular activities in MV-4-11 cells were also confirmed. Significantly, the selective dual inhibitor 41c (HDAC1/BRD4) exhibited synergistic effects against MV-4-11 cells, which strongly induced G0/G1 cell cycle arrest and apoptosis, and the first HDAC6/BRD4(BD2) dual inhibitor was found. This study provides support for selective HDAC/BRD4 dual inhibitors as epigenetic probes based on pyrrolopyridone core for the future biological evaluation in different cancer cell lines.

HETEROCYCLIC COMPOUNDS AS BET INHIBITORS

Novel bromodomain and extraterminal domain (BET) inhibitors and to therapeutic methods of treating conditions and diseases using these novel BET inhibitors are provided.

SULFOXIMINE COMPOUND AS BROMODOMAIN PROTEIN INHIBITOR AND PHARMACEUTICAL COMPOSITION AND MEDICAL USE THEREOF

The present invention relates to a sulfoximine compound represented by formula (I) as a bromodomain protein inhibitor and a pharmaceutically acceptable salt thereof and to a preparation method, pharmaceutical composition, and medical use thereof.

HETEROCYCLIC COMPOUNDS AS BET INHIBITORS

Novel bromodomain and extraterminal domain (BET) inhibitors and to therapeutic methods of treating conditions and diseases using these novel BET inhibitors are provided.

Discovery of N-Ethyl-4-[2-(4-fluoro-2,6-dimethyl-phenoxy)-5-(1-hydroxy-1-methyl-ethyl)phenyl]-6-methyl-7-oxo-1 H-pyrrolo[2,3-c]pyridine-2-carboxamide (ABBV-744), a BET Bromodomain Inhibitor with Selectivity for the Second Bromodomain

The BET family of proteins consists of BRD2, BRD3, BRD4, and BRDt. Each protein contains two distinct bromodomains (BD1 and BD2). BET family bromodomain inhibitors under clinical development for oncology bind to each of the eight bromodomains with similar affinities. We hypothesized that it may be possible to achieve an improved therapeutic index by selectively targeting subsets of the BET bromodomains. Both BD1 and BD2 are highly conserved across family members (>70% identity), whereas BD1 and BD2 from the same protein exhibit a larger degree of divergence (a?40% identity), suggesting selectivity between BD1 and BD2 of all family members would be more straightforward to achieve. Exploiting the Asp144/His437 and Ile146/Val439 sequence differences (BRD4 BD1/BD2 numbering) allowed the identification of compound 27 demonstrating greater than 100-fold selectivity for BRD4 BD2 over BRD4 BD1. Further optimization to improve BD2 selectivity and oral bioavailability resulted in the clinical development compound 46 (ABBV-744).

HETEROCYCLIC COMPOUNDS AS BET INHIBITORS

Novel bromodomain and extraterminal domain (BET) inhibitors and to therapeutic methods of treating conditions and diseases using these novel BET inhibitors are provided.

Pyridine N-oxidation derivative as well as preparation method and application thereof

The invention relates to a pyridine N-oxidation derivative as well as a preparation method and an application thereof, in particular to a compound shown in a general formula (I), a preparation methodof the compound, pharmaceutical composition containing the compound and an application of the compound as a BRD4 inhibitor in treating related diseases such as cancer, inflammation, chronic liver diseases, diabetes, cardiovascular diseases, AIDS and the like, wherein in the general formula (I), all substituent groups are the same as definitions in the description.

Tetrahydroquinoline N-oxidation derivative as well as preparation method and application thereof

The invention relates to tetrahydroquinoline N-oxidation derivative as well as a preparation method and application thereof. The invention relates to a compound shown in a general formula (I) in the specification, a preparation method of the compound, a pharmaceutical composition containing the compound, and application of the compound as a BRD4 inhibitor in treating cancer, inflammation, chronicliver diseases, diabetes mellitus, cardiovascular diseases, AIDS and other related diseases.

BROMODOMAIN INHIBITORS

Provided herein are compounds of formula (I) wherein R 1, Y, L 1, G 1, X 1, X 2, L 2, R 2, R 3, and R 4 have any of the values defined in the specification,

BROMODOMAIN INHIBITORS

Provided are compounds of formula (I),wherein R 1, Y, X 1, X 2, R 2, R 3, R 4, R 5, R 6 and m have any of the values defined in the specification and pharmaceutically acceptable salts thereof, that are useful as agents in the treatment of diseases and conditions, including inflammatory diseases, cancer, and AIDS. Also provided are pharmaceutical compositions comprising compounds of formula (I).